摘要
人凝血因子Ⅶ(FⅦ)是一种维生素K依赖的单链糖蛋白,在体内凝血过程中发挥着重要的作用。重组人活性凝血因子Ⅶ(rhFⅦa)在血管损伤处与组织因子结合后产生足够的凝血酶,从而触发凝血瀑布。rhFⅦa于1999年由美国FDA批准上市(NovoSeven誖雪,尽管结构与血浆提取的FⅦa存在差异,但两者的功能是完全一致的。临床研究表明,rhFⅦ对血友病、血小板减少症和血小板功能障碍、严重创伤、大面积外科手术的止血具有令人满意的止血效果。rhFⅦa由于安全有效,成为治疗血友病、外科创伤出血等的替代疗法。
Human blood coagulation factorⅦ(FⅦ)is a vitamin K-dependent,single-chain glycoprotein that participates in the extrinsic phase of blood coagulation.Recombinant human activated factorⅦ(rhFⅦa)initiates the coagulation cascade by binding to tissue factor at the site of injury and causes the formation of sufficient amounts of thrombin to trigger coag-ulation.rhFⅦa was sanctioned into market in1999by FDA(NovoSeven誖).rhFⅦa and pdFⅦa(derived from human plas-ma)share the identical function though several differences exist in the structure between them.Patients with a variety of other coagulation deficiencies than hemophilia characterized by an impaired thrombin generation and life-threatening bleed-ing have been reported as successfully treated with rhFⅦa.Due to the safety,rhFⅦa has gradually been the substitutive therapy for hemophilia,platelet defects,trauma etc.
出处
《生物技术通讯》
CAS
2004年第3期306-308,共3页
Letters in Biotechnology
基金
军事医学科学院创新基金项目
关键词
人凝血因子Ⅶ
组织因子
血友病
创伤
血小板
recombinant human activated factorⅦ
tissue factor
hemophilia
trauma
